Browsing ICR Divisions by author "Coleman, Niamh"
Now showing items 1-5 of 5
-
CNS cancer immunity cycle and strategies to target this for glioblastoma.
Ameratunga, M; Coleman, N; Welsh, L; Saran, F; Lopez, J (Impact Journals, LLC, 2018-04-27)Immunotherapeutics have revolutionized the management of solid malignancies over the last few years. Nevertheless, despite relative successes of checkpoint inhibitors in numerous solid tumour types, success in tumours of ... -
Detection of circulating tumour cell clusters in human glioblastoma.
Krol, I; Castro-Giner, F; Maurer, M; Gkountela, S; Szczerba, BM; et al. (NATURE PUBLISHING GROUP, 2018-08-14)Human glioblastoma (GBM) is a highly aggressive, invasive and hypervascularised malignant brain cancer. Individual circulating tumour cells (CTCs) are sporadically found in GBM patients, yet it is unclear whether multicellular ... -
Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach.
Coleman, N; Ameratunga, M; Lopez, J (SAGE PUBLICATIONS LTD, 2018-02-26)Over the past decade, precision cancer medicine has driven major advances in the management of advanced solid tumours with the identification and targeting of putative driver aberrations transforming the clinical outcomes ... -
Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience.
Coleman, N; Michalarea, V; Alken, S; Rihawi, K; Lopez, RP; et al. (SPRINGER, 2018-08-01)BACKGROUND: Primary malignant brain tumours (PMBT) constitute less than 2% of all malignancies and carry a dismal prognosis. Treatment options at relapse are limited. First-in-human solid tumour studies have historically ... -
The molecular characterisation of MET addiction in lung cancer
Vivanco, I; Coleman, N (Institute of Cancer Research (University Of London), 2020-08-31)The traditional classification of lung cancer has been radically altered with increased understanding of the molecular alterations and genomic biomarkers that drive the development of the disease. Whilst molecularly targeted ...